The Oestrogen-Regulated pS2-BCEI Protein in Breast Cancer
About one-third of patients with advanced breast cancer respond to hormone therapy . Adequate prescription of this treatment is, therefore, required to devise means of predicting their response. Oestrogen receptor determinations have proved to be effective in this respect: receptor-negative patients displayed remission in less than 5–10% of cases, whereas remission was observed in ∼50% of ER-positive patients. In order to improve this prediction, a search was made for efficient markers of oestrogen action. One of these is the oestrogen-inducible progesterone receptor: ER+ PR+ patients have ∼75% probability to respond to hormone therapy. Also other oestrogen-responsive markers have been defined, for example, Cathepsin D . Random cloning of oestrogen-responsive messenger RNAs was performed independently by 2 groups [3–5]. It allowed to define a messenger RNA called pS2 or BCEI (Breast Cancer Oestrogen Induced), which has been extensively characterised. It was studied not only as a means of predicting response to hormone therapy in advanced breast cancer, but also as a predictor of outcome in early cancer and as a model of oestrogen regulation of a human target gene.
KeywordsBreast Cancer Human Breast Cancer Cell Advanced Breast Cancer Normal Breast Tissue Human Breast Cancer Cell Line
Unable to display preview. Download preview PDF.
- 7.Rio MC, Lepage P, Diemunsch P, Roitsch C and Chambon P: Structure primaire de la proteine humaine pS2. CR Acad Sci III Paris 1988 (307):825–831Google Scholar
- 15.Weaver CA, Springer PA and Katzenellenbogen BS: Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2 chloramphenicol acetyltransferase fusion genes transfected into MCF7 human breast cancer cells. Mol Endocrinol 1988 (2):936–945PubMedCrossRefGoogle Scholar
- 20.Pilat MJ, Hafner M and Brooks SC: Differential induction of pS2 and Cathepsin D mRNAs by structurally altered estrogens. The Endocrine Society 1991 p270Google Scholar
- 25.Brown AMC, Jeltsch JM, Roberts M and Chambon P: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 1984 pp 6344–6348Google Scholar
- 27.Berry M, Nunez AM and Chambon P: Estrogen responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 1986 pp 1218–1222Google Scholar
- 30.Cohen Haguenauer O, Nguyen Van Cong, Prud’homme JF, Jegou-Joubert C, Gross MS, De Tand MF, Milgrom E and Frézal J: A gene expressed in human breast cancer and regulated by estrogen in MCF7 cells is located on chromosome 21. Eighth International Workshop on Human Gene Mapping 1985 (40) p 606Google Scholar
- 33.Prédine J, Spyratos F, Prud’homme JF, Andrieu C, Hacene K, Brunet M, Pallud C and Milgrom E: Enzyme linked immunosorbent assay (ELISA) of pS2 in breast cancers, benign tumors and normal breast tissues. Correlation with prognosis and adjuvant hormonotherapy. Cancer (in press)Google Scholar
- 34.Pallud C, Le Doussal V, Pichon MF, Prud’homme JF, Hacene K and Milgrom E: Immunohistochemistry of pS2 in normal human breast cancer and in various histological forms of breast tumors. Submitted for publicationGoogle Scholar
- 41.Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R and Chambon P: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 1987 (84):9243–9247PubMedCrossRefGoogle Scholar